cyrilzakka/clinical-trials huggingface dataset:
Evaluating the Number of Passes Required for Diagnostic Cell Block During EUS-FNA of Solid Pancreatic Mass Lesions

This study will test the amount of tissue, called "cell block", obtained from your pancreas. Patients who are asked to participate in this study have a growth (mass) in the pancreas that needs a biopsy so a diagnosis can be made. Although we usually perform 2 to 4 passes (number of times the doctor biopsies the mass), at this time we do not know the ideal number of passes needed to obtain adequate amount of tissue for making a diagnosis. The purpose of this study is to compare the amount of tissue obtained with 2 passes versus 4 passes.

Primary Aim:

To compare the number of passes required for obtaining adequate cell block material during EUS-guided FNA of solid pancreatic mass lesions.

Primary Research Hypothesis:

More specimen is required to obtain definitive diagnosis on cell block. This translates to less need for repeat procedures (due to nondiagnostic index procedure due to inadequate FNA passes), prompt treatment to patients and better use of health care resources. Therefore, we will be comparing 2 versus 4 FNA passes to determine which number of FNA pases will yield an adequate diagnostic cell block.

Secondary Aims:

To compare the rate of complications when performing 2 versus 4 EUS-FNA passes of solid pancreatic mass lesions.

Secondary Research Hypothesis:

EUS-guided FNA is a safe procedure with a complication rate of \< 1%. By performing more (four) NA passes one is likely to yield a better quality cell block while at the same time without compromising patient safety.

Eligibility Criteria:
Inclusion Criteria:

1) All patients referred to Florida Hospital Endoscopy Unit for assessment of pancreatic mass lesions that require FNA.

Exclusion Criteria:

1. Age \<19 years
2. Unable to safely undergo EUS for any reason
3. Coagulopathy (INR \>1.6, Prothrombin Time \>18secs, Thrombocytopenia \<80,000 cells/ml)
4. Unable to consent
5. Non-English speaking patients.
6. Participation in any other Clinical Trial (excluding registries and databases)
Evaluating a Video Bystander Program for First-Year College Students

This study will evaluate an innovative video bystander program, which has the potential to be implemented broadly and cost-effectively across college campuses. Half of the participants will receive the video bystander program, and the other half will not.

Sexual violence, which includes both sexual coercion and assault, is a significant problem on college campuses due to its high prevalence and adverse consequences. This research will evaluate an innovative video bystander program, which has the potential to be implemented broadly and cost-effectively across college campuses. We will recruit first-year college students from each of 4 college campuses (Southern Methodist University, Marquette University, William Paterson University, and Stony Brook University).

The video bystander program (TakeCARE) starts with a narrator acknowledging the various demands placed on students in attempting to balance adult responsibilities with the social opportunities of college, as well as the importance of keeping safe while engaging in these social activities. The program describes how likely it is that people they know may become a victim of sexual violence and how they can help "take care of their friends" to help prevent victimization. TakeCARE includes 3 video vignettes that demonstrate ways that students can intervene when they see sexual coercion, relationship violence, or other situations that might result in harm.

After a baseline assessment, students will be randomly assigned to view one of two video programs: TakeCARE (the video bystander program) or a control video program. A post-treatment assessment will be completed within a week of viewing the video program, and follow-up assessments will be completed 2 months and 6 months after baseline.

Eligibility Criteria:
Inclusion Criteria:

* first-year college students

Exclusion Criteria:

-
Effect of Dexmedetomidine and Propofol on Regional Cerebral Tissue Oxygen Saturation

50 patients divided into 2 groups

.Group I Dexmedetomidine infusion. Group II with Propofol infusion

: 50 patients anticipated for open heart surgeries were encompassed in the study. Patients were divided into 2 groups, group P (receiving propofol) and group D (receiving dexmedetomidine) during CPB. Both groups were studied for variations in right and left rScO2 as well as postoperative cognitive dysfunction using the Mini Mental State Examination Score (MMSE) test.

Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing valve surgeries
* Patients undergoing on pump coronary artery bypass grafting surgeries

Exclusion Criteria:

* emergency cases, patients with cervical spine pathology (cervical stenosis, cervical disc herniation, carotid stenosis), patients with cerebral pathology (cerebral strokes, ischemic attacks), patients with Mini Mental State Examination Score (MMSE) of 23 or less, complicated cases with prolongation of the cardiopulmonary bypass period, patients needing moderate hypothermia
The Effect of Aerobic Exercise in Alexithymic Individuals With Chronic Pain

It was aimed to investigate the effect of aerobic exercise on pain, alexithymia level and quality of life in young alexithymic individuals with chronic pain. There is no study in the literature comparing the effectiveness of aerobic exercise on alexithymia and chronic pain. Since our study will be the first study to investigate the subject, we foresee that it is scientifically important and will shed light on future studies. In addition, it is planned to make national or international papers and publications after the study is completed.

In the study, after the necessary permissions are obtained, the Graded Chronic Pain Scale (ECAS) and Toronto Alexithymia Scale-20 (TAS-20) will be sent to the students who are studying at KTO Karatay University and whose age range is between 18-25 years. Among the students who fill out the form voluntarily, individuals who mark the 3rd or 4th option in the first question in the DKAS and who have a total score of 52 and above in the TAS-20 scale will be identified. Among these individuals, a total of 40 people will be included in the study randomly with a computer program. These participants will again be randomly divided into two groups as the control group (n=20) and the exercise group (n=20).

Eligibility Criteria:
Inclusion Criteria:

* To be between the ages of 18-25
* To mark the 3rd or 4th option in the first question in the DKAS
* To have a TAS-20 total score of 61 and above

Exclusion Criteria:

* Presence of any physiological or psychological disease that may interfere with the exercise protocol to be applied
IMTAP : Impact of the Suicide Attempt on the Nearly Entourage in Term of Traumatic Stress and Medico-economic Impact

With 11.000 deaths and 150.000 attempts each year in France, the suicide represents an important public health problem. For each death by suicide, one can count 6 "direct" bereaved people and 20 people in more indirect connection with this mourning (Terra 2001). In term of impact, there is thus 300.000 people (annually) touched by the deaths by suicide and 3.750.000 people (annually) touched by the "suicide attempt" of a close relative. It seems indeed important to have Public Health data on this cascade repercussion of the suicide attempt.

A suicide attempt propagates a suffering cascade on the various circles of the family and close entourage, which can be measured in term of traumatic stress and medico-economic impact.

Objective = To measure the medico-economic impact on the entourage, in the 3 months following the suicide attempt and at 1 year.

Secondary objectives = To measure the impact of the suicide attempt in traumatic term of stress on the close relatives of committing suicide confronted with the suicidal scene To compare the evolution of consumption of care of the close relatives and of committing suicide To measure the evolution of the general health condition of the close relatives and of committing suicide

The study participants (committing suicide it and the relatives) will be recontacted by telephone, after 3 months and to 1 year.

Consumption of care (number of consultations, drugs consumption) of the population of the close relatives of committing suicide will be compared with the data of the Research Institute and Documentation in Economy of Health (IRDES) on the French population (sample of 20.000 people, representative of 95% of the French households).

Eligibility Criteria:
Inclusion Criteria for Suicide attempter :

* Men or women
* Older than 18 years
* Survivor with an suicide attempt going back to less than 15 days

Inclusion Criteria for close relations of committing suicide :

* Men or women
* age more than 18 years
* Members of the entourage of committing suicide
* Living under the same roof as committing suicide it
Ventilation and Perfusion in the Respiratory System

Respiratory failure occurs when the lung fails to perform one or both of its roles in gas exchange; oxygenation and/or ventilation. Presentations of respiratory failure can be mild requiring supplemental oxygen via nasal cannula to more severe requiring invasive mechanical ventilation as see in acute respiratory distress syndrome (ARDS).It is important to provide supportive care through noninvasive respiratory support devices but also to minimize risk associated with those supportive devices such as ventilator induced lung injury (VILI) and/or patient self-inflicted lung injury (P-SILI). Central to risk minimization is decreasing mechanical stress and strain and optimizing transpulmonary pressure or the distending pressure across the lung, minimizing overdistention and collapse. Patient positioning impacts ventilation/perfusion and transpulmonary pressure. Electrical impedance tomography (EIT) is an emerging technology that offers a noninvasive, real-time, radiation free method to assess distribution of ventilation at the bedside. The investigators plan to obtain observational data regarding distribution of ventilation during routine standard of care in the ICU, with special emphasis on postural changes and effects of neuromuscular blockade, to provide insight into ventilation/perfusion matching, lung mechanics in respiratory failure, other pulmonary pathological processes.


Eligibility Criteria:
Inclusion Criteria:

* 18 years or older
* admitted to UC San Diego La Jolla or Hillcrest Campus Intensive Care Units
* Patient requiring supplemental oxygen (including but no limited to nasal cannula, high flow devices, noninvasive positive pressure ventilation or mechanical ventilation

Exclusion Criteria:

* \<18 years
* Chest wall, anatomical, physical abnormalities, skin integrity issues precluding placement of electrode belt in direct contact with skin
* Patient is too unstable to position the belt/electrodes or tolerate head of bed changes
* Confirmed or suspected intracranial bleed, stroke, edema
* Active implants (i.e. implantable electronic devices such as pacemakers, cardioverter defibrillators, neurostimulators) or if device compatibility is in doubt
* Pregnant or lactating patients as safety and efficacy for use of EIT in such cases has not been verified
Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Cryptococcus Neoformans Infection in Patients Not Infected With HIV and Complications Associated With Cryptococcus Neoformans Infection

Innate immunity plays an important role for fungal recognition and initiation of fungicidal activity. We hypothesize that subtle differences in different molecules of innate immunity may contribute to either the predisposition or clinical course of infection with Cryptococcus neoformans. To test this hypothesis, we propose to analyze the allelic frequencies of 15 different genes (mannose binding lectin, Fc-gamma receptor IIa and IIb, Fc-gamma receptors IIIa and IIIb, myeloperoxidase, tumor necrosis factor-alpha and -beta, interleukin 1A and 1B, interleukin-1 receptor antagonist, interleukin-10, NRAMP-1, chitotriosidase, and chemokine receptor 5) and their intragenic polymorphic forms and to compare this data to the incidence and severity of C neoformans infection. With this study we hope to identify a group of molecules of innate immunity which influence the risk and severity of invasive C neoformans infection.

Innate immunity plays an important role for fungal recognition and initiation of fungicidal activity. We hypothesize that subtle differences in different molecules of innate immunity may contribute to either the predisposition or clinical course of infection with Cryptococcus neoformans. To test this hypothesis, we propose to analyze the allelic frequencies of 15 different genes (mannose binding lectin, Fc-gamma receptor IIa and IIb, Fc-gamma receptors IIIa and IIIb, myeloperoxidase, tumor necrosis factor-alpha and -beta, interleukin 1A and 1B, interleukin-1 receptor antagonist, interleukin-10, NRAMP-1, chitotriosidase, and chemokine receptor 5) and their intragenic polymorphic forms and to compare this data to the incidence and severity of C neoformans infection. With this study we hope to identify a group of molecules of innate immunity which influence the risk and severity of invasive C neoformans infection.

Eligibility Criteria:
* INCLUSION CRITERIA:

Patients diagnosed with Cryptococcus neoformans infection will be identified from a data base overseen by Dr. Peter Pappas.

Only patients diagnosed and treated in the United States and Canada will be included in this analysis.

Only patients who are not coinfected with HIV will be included in the study.

Patient samples will be collected and clinical data will be evaluated only after signed informed consent has been obtained.
A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis

The reason for this study is to see if the study drug LY3375880 is safe and effective in adults with moderate-to-severe atopic dermatitis (AD).


Eligibility Criteria:
Inclusion Criteria:

* Participants must have diagnosis of AD \>= 12 months according to the American Academy of Dermatology criteria.
* Participants must have moderate to severe AD at screening and randomization.
* Participants must have inadequate response to topical medications within 6 months of screening (or history of intolerance).

Exclusion Criteria:

* Participants must not have concurrent treatment with topical or systemic treatments for AD.
Maintenance Neoral Monotherapy Compared to Bitherapy in Renal Transplantation

We have previously defined factors that predict the long term success of maintenance CsA monotherapy (CsAm) after kidney transplantation : donor age \< 40 years, serum creatinine level at the initiation of CsAm £ 125 µmol/L, no rejection episode before CsAm initiation. We have also shown that the 8-year graft survival in 329 selected patients enrolled in maintenance CsA-m was 84 % (Hurault de Ligny et al, Transplantation, 2000 ; 69 : 1327-1332). These results were obtained with an old formulation of cyclosporin, azathioprine, steroid withdrawal over the first year and induction antibody. This prospective randomized multicentre study was designed to clarify whether maintenance Neoral + MMF or Neoral + AZA is better than a CsAm and wether Neoral + MMF is better than Neoral + AZA in low immunological risk cadaveric kidney transplant recipients.

Between july 1998 and january 2004 selected patients were randomly assigned equally within each centre to receive CsAm or bitherapy with equally CsA + MMF or CsA + AZA.

Eligibility Criteria:
* Inclusion criteria:

  * Primary cadaveric renal transplant with induction therapy, delayed Neoral, MMF and prednisone
  * Steroid withdrawal \>= 3 months before enrolment
  * Bitherapy Neoral + CellCept
  * Follow up time since transplantation : 11-24 months
  * Recipient age \>= 25 years
  * Donor age \<= 45 years
  * Serum creatinine level \<= 125 µmol/L and/or calculated creatinine clearance \>= 50 ml/mn (CG formula)
  * No or only one steroid-sensitive acute rejection episode during the first year post-transplantation
  * PRA \<= 25 %
  * Written informed consent
* Exclusion Criteria:

  * Living donor transplantation
  * Recipient receiving tacrolimus
  * Azathioprine intolerance
  * Thrombopenia \< 100 000/mm³
  * Neutropenia \< 1500/mm³
  * Hemoglobinemia \<= 8g/dl
  * On going infection
Pancreatic Surgical Database

This data base has been set in order to gather medical and surgical information from patients who have undergone surgery for pancreatic cancer, at Institut Paoli Calmettes or Assistance Publique des Hôpitaux de Marseille, France.


Eligibility Criteria:
Inclusion Criteria:

* Patient \>18 ans
* Surgery for a pancreatic cancer

Exclusion Criteria:

* Patient refusal to participate in the study
A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

The purpose of this study is to determine whether Daikenchuto(TU-100)is effective in the treatment of Crohn's disease.

Crohn's disease, a chronic condition resulting in inflammation of the gastrointestinal tract (GI), causes a person to experience persistent symptoms of inflammatory bowel disease, including abdominal pain, nausea, vomiting, rectal bleeding, diarrhea, and constipation, with infrequent bowel movements that are at times accompanied by a sensation of incomplete emptying after having a bowel movement. Tsumura's TU-100 is a modern herbal product that has been approved as a prescription drug in Japan. Several lines of evidence indicate that TU-100 attenuates intestinal inflammation in Crohn's disease by increasing intestinal blood flow and stimulating a protective lining of intestinal mucus which produces an anti-inflammatory effect. TU-100 may attenuate pathological changes in the intestine and reduce symptoms in patients with Crohn's disease.

Eligibility Criteria:
Inclusion Criteria:

* provide written informed consent
* ability to orally ingest study medication
* male or female between 18 to 75 inclusive
* diagnosed with Crohn's disease for at least 3 months
* CDAI score of 220-300 at screening
* sexually active participants of childbearing potential must agree to birth control
* no clinically significant conditions which the doctor would feel exclusionary
* stable medication (including probiotics)

Exclusion Criteria:

* history of any bowel condition that may interfere with the evaluation of the study drug
* positive stool cultures
* currently pregnant or lactating
* receiving total parenteral nutrition
* history of alcohol or drug abuse within one year
* history of malignancy within 5 years
* current use of anticholinergic agents, antidepressants during the study, warfarin, prokinetics, antipsychotic agents or narcotic analgesics
* treatment with Anti-TNF agents 12 weeks before screening
* treatment with corticosteroids four weeks prior to screening
* treatment with cyclosporine or tacrolimus eight weeks prior to screening
* presence of a poorly controlled medical condition
* history of allergic reaction to ginseng, ginger or sichuan pepper
* any use of supplemental ginger, ginseng and Sichuan powder 2 weeks prior to and through course of the trial
* current use of any of the following herbal medications: Boswellia, Cat's claw (Uncaria tomentosa), Cayenne pepper, Echinacea, Horsetail (Equisetum), Hops, Lady's mantle (Alchemilla), Marshmallow root (Althaea), Slippery elm (Ulmus rubra) Turmeric and White Willow (Salix alba)
* history of celiac disease
* current diagnosis of lactose intolerance
* history of any other investigational medication within 30 days of enrolling in study
* unsuitability as determined by the study doctor
Modifiable Variables in Parkinsonism (MVP)

We are trying to identify factors associated with improved quality of life and fewer PD symptoms. We are attempting to identify practices, beliefs, and therapies used by individuals who report excellent quality of life, few PD symptoms, and reduced rates of progression. After agreeing to participate, we will ask participants to fill our questionnaires about their experience with PD, their health in general, along with their food intake every six months for five years.

This is a prospective, observational study designed to describe disease progression, symptom change, quality of life, diet and lifestyle habits among patients with Parkinson's disease (PD). This study will identify and describe those individuals with the highest quality of life and least amount of disease activity, in order to describe medication, diet, and lifestyle patterns associated with a lack of PD disease progression and high quality of life.

Participants will be asked to complete online surveys every six months for five years. The time requirement is about an hour to an hour and a half every six months. Participants do not need to answer questions if they do not feel comfortable answering.

At each six month time point we will send participants an email with the link to the CAM Care in PD survey, a questionnaire about health and wellbeing (completed in REDCap). After participants have completed this survey we will send participants a link to the second survey, about dietary intake (completed on ASA24.gov). Because there is a designated window of time during which surveys must be completed, participants may receive a gentle reminder from us if time is running out.

This study is not designed to provide care. Participants are encouraged to consult with any providers you wish. Participants will not directly benefit from the study, but information gathered during the course of this study may help us begin to assess the longer-term effects of complementary and integrative care on health, disease progression and quality of life in PD patients.

Eligibility Criteria:
Inclusion Criteria:

* Parkinson's disease (PD)
* Parkinsonism
* Parkinson-plus syndromes (e.g. Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), Corticobasal degeneration (CBGD), Dementia with Lewy bodies)
* Must have online access, an email address, basic computer literacy
* Must be willing to complete online surveys every 6 months for 5 years

Exclusion Criteria:

* Inability to read/write English
* Inability or unwillingness to complete surveys every six (6) months (\~90 min)